Mr. Edward Chan serves as Principal at 1315 Capital. He joined 1315 Capital in 2016 after spending 5 years at NaviMed Capital, most recently as a Vice President. Prior to joining NaviMed Capital, he was part of the healthcare investment team at Siemens Venture Capital. Based out of Boston and Beijing, he evaluated and sourced commercial and growth stage healthcare deals worldwide, performed research on various market sectors, and supported portfolio companies. He also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. Edward started his career developing and commercializing a molecular diagnostic product at a venture backed company. Prior to 1315 Capital, he was actively involved, at both NaviMed and Siemens Ventures, in the following investments: CenterPointe Behavioral Health System, Lucent Health Solutions, China Diagnostics Medical Corporation (acquired by Actis Capital), BioImagene (acquired by Roche), RadPharm (acquired by JLL Partners), U-Systems (acquired by GE), MD Datacor (acquired by Noridian Mutual Insurance), Zonare (acquired by Mindray), and Cylex (acquired by Viracor-IBT). He received a BSc in Biomedical Engineering from Johns Hopkins University and an MBA from the Wharton School at the University of Pennsylvania, where he was President of the Healthcare Club.